SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (1671)7/28/1999 2:44:00 PM
From: PSC  Read Replies (1) of 1762
 
Dear Maurice:

These patients treated with Rituxan have some level of immunodeficiency anyway if they have lymphoma. Whether the Rituxan adds to that level of immunodeficiency or not is the question. Nonetheless, given the spectacular results with minimum other toxicity, TB prophylaxis with either a BCG vaccine, or some low dose anti-TB meds (like INH) should probably take care of this and you can be sure the investigators for IDEC are looking into this.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News